Details for Patent: 8,327,844
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,327,844 protect, and when does it expire?
Patent 8,327,844 protects ONZETRA XSAIL and XHANCE and is included in two NDAs.
This patent has one hundred and fifty-four patent family members in twenty-six countries.
Summary for Patent: 8,327,844
Title: | Nasal delivery method |
Abstract: | A delivery device (20, 22) for and a method of delivering a substance to the nasal airway (1) of a subject, in particular the posterior region of the nasal airway, the delivery device comprising: a closure unit for causing the closure of the oropharyngeal velum of the subject; and a delivery unit for delivering a gas flow entraining a substance to one of the nostrils of the subject at such a driving pressure as to flow around the posterior margin of the nasal septum and out of the other nostril of the subject, wherein the delivery unit comprises a nosepiece (30, 40, 58, 82, 102, 132) which includes an outlet through which the gas flow is in use delivered to the one nostril and a sealing member for sealing the one nostril to the outlet such as in use to prevent the escape of the gas flow through the one nostril. |
Inventor(s): | Djupesland; Per Gisle (Oslo, NO) |
Assignee: | OptiNose AS (Oslo, NO) |
Application Number: | 10/813,326 |
Patent Claim Types: see list of patent claims | Use; Delivery; Device; Formulation; |
Drugs Protected by US Patent 8,327,844
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY | See Plans and Pricing | ||||
Optinose Us Inc | XHANCE | fluticasone propionate | SPRAY, METERED;NASAL | 209022-001 | Sep 18, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,327,844
International Family Members for US Patent 8,327,844
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 285810 | See Plans and Pricing | |||
Austria | 422923 | See Plans and Pricing | |||
Austria | 427130 | See Plans and Pricing | |||
Austria | 487506 | See Plans and Pricing | |||
Austria | 506983 | See Plans and Pricing | |||
Austria | 514445 | See Plans and Pricing | |||
Australia | 2002255224 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |